UB Paderborn / Katalog / Suche / in CDI

Dialogues autour du patrimoine: L’histoire, un enjeu de communication ?

2023

Volltextzugriff (PDF)

Dialogues autour du patrimoine

2023

Volltextzugriff (PDF)

Chapitre 8. Sentir pour ressentir, la médiation olfactive au service des œuvres d’art

Saillard, Christine

2023

Volltextzugriff (PDF)

Influence of the microstructure on the corrosion behaviour of 2024 aluminium alloy coated with a trivalent chromium conversion layer

Corrosion science, 2018-09, Vol.142, p.119-132

2018

Volltextzugriff (PDF)

Comparative analysis of the anticorrosive properties of trivalent chromium conversion coatings formed on 2024-T3 and 2024-T351 aluminium alloys

Corrosion science, 2020-05, Vol.167, p.108508, Article 108508

2020

Volltextzugriff (PDF)

Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults

Leukemia & lymphoma, 2021-03, Vol.62 (3), p.620-629

2021

Volltextzugriff (PDF)

Oncogenetic landscape of lymphomagenesis in coeliac disease

Gut, 2022-03, Vol.71 (3), p.497

2022

Volltextzugriff (PDF)

Immune response and survival of Circulifer haematoceps to Spiroplasma citri infection requires expression of the gene hexamerin

Developmental and comparative immunology, 2016-01, Vol.54 (1), p.7-19

2016

Volltextzugriff (PDF)

Effect of trivalent chromium process on fatigue lifetime of 2024-T3 aluminium alloy

Materials science & engineering. A, Structural materials : properties, microstructure and processing, 2019-01, Vol.743, p.322-326

2019

Volltextzugriff (PDF)

Hepatic dysfunction impairs prognosis in critically ill patients with hematological malignancies: A post-hoc analysis of a prospective multicenter multinational dataset

Journal of critical care, 2021-04, Vol.62, p.88-93

2021

Volltextzugriff (PDF)

IDH Mutations Identify a Subgroup of NPM1 Patients with a More Favorable Prognosis. a Retrospective Multicenter Study of the Filo Group

Blood, 2020-11, Vol.136 (Supplement 1), p.39-40

2020

Volltextzugriff (PDF)

Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study

Journal of antimicrobial chemotherapy, 2018-08, Vol.73 (8), p.2120-2128

2018

Volltextzugriff (PDF)

Multidimensional Approach to Invasive Species Prevention

Environmental science & technology, 2013-02, Vol.47 (3), p.1216-1221

2013

Volltextzugriff (PDF)

Pharmacological data of a successful 4‐days‐a‐week regimen in HIV antiretroviral therapy (ANRS 162‐4D trial)

British journal of clinical pharmacology, 2021-04, Vol.87 (4), p.1930-1939

2021

Volltextzugriff (PDF)

Low-dose ritonavir-boosted darunavir in virologically suppressed HIV-1-infected adults: an open-label trial (ANRS 165 Darulight)

Journal of antimicrobial chemotherapy, 2018-08, Vol.73 (8), p.2129-2136

2018

Volltextzugriff (PDF)

Maintenance darunavir/ritonavir monotherapy to prevent perinatal HIV transmission, ANRS-MIE 168 MONOGEST study

Journal of antimicrobial chemotherapy, 2023-07, Vol.78 (7), p.1711-1722

2023

Volltextzugriff (PDF)

Atompräzise organometallische Zinkcluster

Angewandte Chemie, 2016-03, Vol.128 (10), p.3344-3349

2016

Volltextzugriff (PDF)

Safety and Immunogenicity of a Monovalent 2009 Influenza A/H1N1v Vaccine Adjuvanted With AS03A or Unadjuvanted in HIV-Infected Adults: A Randomized, Controlled Trial

The Journal of infectious diseases, 2011-07, Vol.204 (1), p.124-134

2011

Volltextzugriff (PDF)

Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial

Journal of antimicrobial chemotherapy, 2018-03, Vol.73 (3), p.738-747

2018

Volltextzugriff (PDF)

Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial

Journal of antimicrobial chemotherapy, 2020-03, Vol.75 (3), p.628-639

2020

Volltextzugriff (PDF)

Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study

Journal of antimicrobial chemotherapy, 2014-06, Vol.69 (6), p.1648-1652

2014

Volltextzugriff (PDF)

Long-term immunogenicity of two doses of 2009 A/H1N1v vaccine with and without AS03(A) adjuvant in HIV-1-infected adults

AIDS (London), 2013-01, Vol.27 (1), p.87-93

2013

Volltextzugriff (PDF)

Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART

Journal of antimicrobial chemotherapy, 2016-04, Vol.71 (4), p.1056-1062

2016

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Dialogues autour du patrimoine: L’histoire, un enjeu de communication ?

Dialogues autour du patrimoine

Chapitre 8. Sentir pour ressentir, la médiation olfactive au service des œuvres d’art

Influence of the microstructure on the corrosion behaviour of 2024 aluminium alloy coated with a trivalent chromium conversion layer

Comparative analysis of the anticorrosive properties of trivalent chromium conversion coatings formed on 2024-T3 and 2024-T351 aluminium alloys

Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults

Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial

Oncogenetic landscape of lymphomagenesis in coeliac disease

Immune response and survival of Circulifer haematoceps to Spiroplasma citri infection requires expression of the gene hexamerin

Effect of trivalent chromium process on fatigue lifetime of 2024-T3 aluminium alloy

Hepatic dysfunction impairs prognosis in critically ill patients with hematological malignancies: A post-hoc analysis of a prospective multicenter multinational dataset

IDH Mutations Identify a Subgroup of NPM1 Patients with a More Favorable Prognosis. a Retrospective Multicenter Study of the Filo Group

Bone mineral density and inflammatory and bone biomarkers after darunavir–ritonavir combined with either raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial

Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study

Multidimensional Approach to Invasive Species Prevention

Pharmacological data of a successful 4‐days‐a‐week regimen in HIV antiretroviral therapy (ANRS 162‐4D trial)

Low-dose ritonavir-boosted darunavir in virologically suppressed HIV-1-infected adults: an open-label trial (ANRS 165 Darulight)

Maintenance darunavir/ritonavir monotherapy to prevent perinatal HIV transmission, ANRS-MIE 168 MONOGEST study

Atompräzise organometallische Zinkcluster

Safety and Immunogenicity of a Monovalent 2009 Influenza A/H1N1v Vaccine Adjuvanted With AS03A or Unadjuvanted in HIV-Infected Adults: A Randomized, Controlled Trial

Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial

Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial

Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study

Long-term immunogenicity of two doses of 2009 A/H1N1v vaccine with and without AS03(A) adjuvant in HIV-1-infected adults

Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART

Suchergebnisse filtern